<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(2)</volume><submitter>Qu S</submitter><pubmed_abstract>&lt;b>Significance&lt;/b>: Platelet-rich plasma (PRP) may be a potential drug for treatment of chronic refractory ulcers, which increase the risk of systemic infection and local canceration. However, the efficacy and safety of clinical application of PRP are still controversial. Thus, this study was aimed to assess the efficacy and safety of PRP in patients with chronic ulcers. &lt;b>Recent Advances:&lt;/b> For this meta-analysis, Cochrane's Library, MEDLINE, EMBASE, PubMed, Web of Science, and CINAHL (Cumulate Index to Nursing and Allied Health Literature) databases were searched. Results were pooled using a random-effects model. The primary outcome was the proportion of completely healed chronic ulcers. &lt;b>Critical Issues:&lt;/b> Seventeen randomized controlled trials were included. Compared with the c</pubmed_abstract><journal>Advances in wound care</journal><pagination>56-69</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9831249</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Clinical Studies on Platelet-Rich Plasma Therapy for Chronic Cutaneous Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</pubmed_title><pmcid>PMC9831249</pmcid><pubmed_authors>Qu S</pubmed_authors><pubmed_authors>Huang S</pubmed_authors><pubmed_authors>Rong Y</pubmed_authors><pubmed_authors>Wang P</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Dong Y</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Hu Z</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Tang B</pubmed_authors><pubmed_authors>Zhu W</pubmed_authors><pubmed_authors>Xu H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical Studies on Platelet-Rich Plasma Therapy for Chronic Cutaneous Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</name><description>&lt;b>Significance&lt;/b>: Platelet-rich plasma (PRP) may be a potential drug for treatment of chronic refractory ulcers, which increase the risk of systemic infection and local canceration. However, the efficacy and safety of clinical application of PRP are still controversial. Thus, this study was aimed to assess the efficacy and safety of PRP in patients with chronic ulcers. &lt;b>Recent Advances:&lt;/b> For this meta-analysis, Cochrane's Library, MEDLINE, EMBASE, PubMed, Web of Science, and CINAHL (Cumulate Index to Nursing and Allied Health Literature) databases were searched. Results were pooled using a random-effects model. The primary outcome was the proportion of completely healed chronic ulcers. &lt;b>Critical Issues:&lt;/b> Seventeen randomized controlled trials were included. Compared with the c</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2026-07-09T12:16:42.91Z</modification><creation>2025-04-19T17:56:25.057Z</creation></dates><accession>S-EPMC9831249</accession><cross_references><pubmed>33607926</pubmed><doi>10.1089/wound.2020.1186</doi></cross_references></HashMap>